Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. Scarfo L, Heltai S, Albi E, Scarano E, et al. Blood 2022;140:2348-2357.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Scarfo L, Heltai S, Albi E, Scarano E, et al. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. Blood 2022;140:2348-2357.
PMID: 35921541